Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Platzbecker, Uwe  [Clear All Filters]
2022
Itzykson R, Santini V, Thépot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol. 2022:JCO2200437.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, et al. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022.
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LKatharina, Backhaus D, Brauer D, Goldmann K, Franke G-N, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2022.
Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke G-N, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission. Blood Adv. 2022.
Saini SKumar, Holmberg-Thydén S, Bjerregaard A-M, Unnikrishnan A, Dorfmüller S, Platzbecker U, Tirado-Gonzalez I, Bonig H, Fassi DEl, Grønbæk K, et al. Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia. 2022.
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke G-N, Herling M, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170.